Skip to Content

Admelog Dosage

Generic name: INSULIN LISPRO 100U in 1mL
Dosage form: injection, solution

Medically reviewed by Drugs.com. Last updated on Nov 30, 2020.

Important Administration Instructions

  • Always check insulin labels before administration [see Warnings and Precautions (5.4)].
  • Inspect ADMELOG visually before use. It should appear clear and colorless. Do not use ADMELOG if particulate matter or coloration is seen.
  • Use ADMELOG SoloStar prefilled pen with caution in patients with visual impairment who may rely on audible clicks to dial their dose.
  • Do NOT mix ADMELOG with other insulins when administering using a continuous subcutaneous infusion pump.

Route of Administration

Subcutaneous Injection

  • Administer the dose of ADMELOG within fifteen minutes before a meal or immediately after a meal.
  • ADMELOG administered by subcutaneous injection should generally be used in regimens with intermediate or long-acting insulin.
  • ADMELOG should be administered by subcutaneous injection in the abdominal wall, thigh, upper arm, or buttocks. Rotate injection site within the same region (abdomen, thigh, upper arm, or buttocks) from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2), Adverse Reactions (6)].
  • During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.2)].
  • The ADMELOG SoloStar prefilled pen dials in 1-unit increments.

Continuous Subcutaneous Infusion (Insulin Pump)

  • Administer ADMELOG by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer. Rotate infusion sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2), Adverse Reactions (6)].
  • During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions (5.2)].
  • Follow healthcare provider recommendations when setting basal and mealtime infusion rate.
  • Do NOT dilute or mix ADMELOG when administering by continuous subcutaneous infusion.
  • Change ADMELOG in the pump reservoir at least every 7 days.
  • Change the infusion sets and the infusion set insertion site at least every 3 days.
  • Do NOT expose ADMELOG in the pump reservoir to temperatures greater than 98.6°F (37°C).
  • Use ADMELOG in accordance with the insulin infusion pump systems instructions for use. See the insulin infusion pump system labeling to determine if ADMELOG can be used with the pump system.

Intravenous Administration

Dosage Information

  • Individualize and adjust the dosage of ADMELOG based on route of administration, the individual's metabolic needs, blood glucose monitoring results, and glycemic control goal.
  • Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function, or during acute illness [see Warnings and Precautions (5.2, 5.3) and Use in Specific Populations (8.6, 8.7)].
  • If changing patients from another insulin lispro product to ADMELOG, the dose of ADMELOG should be the same as the other insulin lispro product [see Warnings and Precautions (5.2)].

Dosage Adjustment Due to Drug Interactions

  • Dosage adjustment may be needed when ADMELOG is coadministered with certain drugs [see Drug Interactions (7)].
  • Dosage adjustment may be needed when switching from another insulin to ADMELOG [see Warnings and Precautions (5.2)].
  • Do NOT mix ADMELOG with any other insulin.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Frequently Asked Questions